
## Raymond B Mailhot Vega

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7475806/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer, 2013, 119, 4299-4307.	4.1	64
2	Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 11-18.	0.8	49
3	Second tumor risk in children treated with proton therapy. Pediatric Blood and Cancer, 2021, 68, e28941.	1.5	23
4	Estimating child mortality associated with maternal mortality from breast and cervical cancer. Cancer, 2019, 125, 109-117.	4.1	22
5	Treatment Outcomes After Proton Therapy for Ewing Sarcoma of the Pelvis. International Journal of Radiation Oncology Biology Physics, 2020, 107, 974-981.	0.8	22
6	Cost in perspective: direct assessment of American market acceptability of Co-60 in gynecologic high-dose-rate brachytherapy and contrast with experience abroad. Journal of Contemporary Brachytherapy, 2018, 10, 503-509.	0.9	14
7	Patterns of Failure in Parameningeal Alveolar Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 325-333.	0.8	11
8	Local Control After Proton Therapy for Pediatric Chordoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1406-1413.	0.8	10
9	Using Robust Optimization for Skin Flashing in Intensity Modulated Radiation Therapy for Breast Cancer Treatment: A Feasibility Study. Practical Radiation Oncology, 2020, 10, 59-69.	2.1	9
10	Incorporation of the LETd-weighted biological dose in the evaluation of breast intensity-modulated proton therapy plans. Acta OncolÃ <sup>3</sup> gica, 2021, 60, 252-259.	1.8	9
11	Dosimetric consequences of image guidance techniques on robust optimized intensity-modulated proton therapy for treatment of breast Cancer. Radiation Oncology, 2020, 15, 47.	2.7	8
12	Pathways for Recruiting and Retaining Women and Underrepresented Minority Clinicians and Physician Scientists Into the Radiation Oncology Workforce: A Summary of the 2019 ASTRO/NCI Diversity Symposium Session at the ASTRO Annual Meeting. Advances in Radiation Oncology, 2020, 5, 798-803.	1.2	7
13	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. International Journal of Radiation Oncology Biology Physics, 2021, 109, 220-230.	0.8	7
14	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2022, 112, 158-166.	0.8	7
15	Demographics of ASTRO Student Members and Potential Implications for Future U.S. Radiation Oncology Workforce Diversity. Advances in Radiation Oncology, 2022, 7, 100834.	1.2	7
16	Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41. International Journal of Radiation Oncology Biology Physics, 2022, 113, 542-551.	0.8	7
17	Proton radiotherapy for infant rhabdomyosarcoma: Rethinking young age as an adverse prognostic factor. Radiotherapy and Oncology, 2021, 163, 215-220.	0.6	4
18	Novel Pilot Curriculum for International Education of Lymphoma Management Using E-Contouring. Journal of Global Oncology, 2018, 4, 1-9.	0.5	3

#	Article	IF	CITATIONS
19	Outcomes following limitedâ€volume proton therapy for multifocal spinal myxopapillary ependymoma. Pediatric Blood and Cancer, 2021, 68, e28820.	1.5	3
20	Cross-Sectional International Survey to Determine the Educational Interests of Spanish-Speaking Latin American Radiation Oncologists. JCO Global Oncology, 2021, 7, 29-34.	1.8	3
21	RBEâ€weighted dose and its impact on the risk of acute coronary event for breast cancer patients treated with intensity modulated proton therapy. Journal of Applied Clinical Medical Physics, 2022, 23, .	1.9	3
22	Modern Therapy for Chest Wall Ewing Sarcoma: An Update of the XXX Experience. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	3
23	Patient-specific quality assurance and plan dose errors on breast intensity-modulated proton therapy. Physica Medica, 2020, 77, 84-91.	0.7	2
24	Bicentric Treatment Outcomes After Proton Therapy for Nonmyxopapillary High-Grade Spinal Cord Ependymoma in Children. International Journal of Radiation Oncology Biology Physics, 2022, 112, 335-341.	0.8	2
25	Modern Therapy for Spinal and Paraspinal Ewing Sarcoma: An Update of the University of Florida Experience. International Journal of Radiation Oncology Biology Physics, 2022, 113, 161-165.	0.8	2
26	Hyperfractionated-Accelerated Reirradiation with Proton Therapy for Radiation-Associated Breast Angiosarcoma. International Journal of Particle Therapy, 2022, 8, 55-67.	1.8	2
27	Broadening the Tent with Intentional Spaces. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1118-1119.	0.8	1
28	A positive approach: advances in proton therapy for the treatment of mediastinal lymphoma. Expert Review of Hematology, 2020, 13, 197-200.	2.2	1
29	Pulmonary dose tolerance in hemithorax radiotherapy for Ewing sarcoma of the chest wall: Are we overestimating the risk of radiation pneumonitis?. Pediatric Blood and Cancer, 2021, 68, e29287.	1.5	1
30	ASO Visual Abstract: A 5-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1–4N1–3M0ÂBreast Cancer. Annals of Surgical Oncology, 2021, , 1.	1.5	0
31	Pericardial Effusion during Proton Therapy in a Patient with Chemorefractory Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 76-81.	1.8	0
32	¡Aviso, Médicos!: The Effect of Direct Patient-Doctor Communication Cannot Be Overlooked. International Journal of Radiation Oncology Biology Physics, 2021, 111, 865-866.	0.8	0
33	Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity. Value in Health, 2021, 25, 171-177.	0.3	0